Latest News:

Tufts CSDD Demonstrates Multi-Million-Dollar Benefits of Translational Pharmaceutics®

Downloading our Case Studies

You are about to download this document, please enter your contact details below to start downloading.

Case Studies

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is taking advantage of Quotient Sciences’ Translational Pharmaceutics® platform and First-In-Human program for the development of BCX4161, a promising candidate for the treatment of hereditary angioedema.

Would you like to receive further scientific content including case studies, whitepapers and seminar and webinar invitations?
You can find out how we handle your personal information in our privacy policy here.

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.